Lupin Strengthens U.S. Respiratory Portfolio with FDA Tentative Approval

received tentative approval from the U.S. FDA for its Revefenacin Inhalation Solution (175 mcg/3 mL), a generic version of Yupelri used for treating Chronic Obstructive Pulmonary Disease (COPD). The approval marks another step in Lupin’s strategy to expand its respiratory product portfolio in the highly regulated U.S. market. According to IQVIA data for March 2026, the reference product recorded annual U.S. sales of nearly USD 260.7 million, highlighting the sizeable market opportunity for the company. The development also reflects Lupin’s continued focus on strengthening its presence in the global generics space through specialized respiratory therapies and complex product approvals. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.